Enzon Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Piscataway NJ United States (1981)
Status: Acquired by NPS Pharma (2009) → now Takeda (2018)

Organization Overview

First Clinical Trial
2001
NCT00023166
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Enzon Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 1)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Cryptococcosis (Phase 4)

Fever (Phase 1)

Hematologic Diseases (Phase 1)

Hot Flashes (Phase 1)

Infections (Phase 3)

Invasive Fungal Infections (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lung Diseases (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Meningeal Carcinomatosis (Phase 2)

Meningitis (Phase 2)

Multiple Myeloma (Phase 1)

Mycoses (Phase 3)

Myelodysplastic Syndromes (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 1)

Neutropenia (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Preleukemia (Phase 1)

Prostatic Neoplasms (Phase 1)

Sarcoma (Phase 2)

Stomach Neoplasms (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 29